SEELOS THERAPEUTICS, INC. - FORM 10-K - EX-32.1 - 906 CERTIFICATE - March 17, 2020

Attached files

file filename
EX-4.25 - DESCRIPTION OF SECURITIES OF SEELOS THERAPEUTICS, INC. - SEELOS THERAPEUTICS, INC.exh4-25.htm
EX-31.1 - 302 CERTIFICATE - SEELOS THERAPEUTICS, INC.exh31-1.htm
EX-23.1 - CONSENT - SEELOS THERAPEUTICS, INC.exh23-1.htm
EX-10.30 - AMENDMENT TO LICENSE AGREEMENT, DATED AS OF FEBRUARY 8, 2019, BY AND AMONG LIGAN - SEELOS THERAPEUTICS, INC.exh10-30.htm
10-K - 10-K - SEELOS THERAPEUTICS, INC.body10k.htm

EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND INTERIM CHIEF FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Raj Mehra, Ph.D., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report on Form 10-K of Seelos Therapeutics, Inc. for the year ended December 31, 2019 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Annual Report on Form 10-K fairly presents, in all material respects, the financial condition and results of operations of Seelos Therapeutics, Inc.

 
     

Date: March 17, 2020

By:

/S/ Raj Mehra, Ph.D.

 

Name:

Raj Mehra, Ph.D. 

 

Title:

Chief Executive Officer, President and Interim Chief Financial Officer

 

SEELOS THERAPEUTICS, INC. Reports